Compare Natera Inc. Common Stock (NTRA) vs YPF Sociedad Anonima American Depositary Shares (YPF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs YPF Sociedad Anonima American Depositary Shares — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while YPF Sociedad Anonima American Depositary Shares trades at $52.38 (market cap $20.31B). The key difference: Natera Inc. Common Stock is far larger — about 2.8× YPF Sociedad Anonima American Depositary Shares's market cap, and Natera Inc. Common Stock is more actively traded (1,131,157 versus 1,015,599). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and YPF Sociedad Anonima American Depositary Shares for 6 Days on average.
| NTRA | YPF | |
|---|---|---|
Market Cap | $57.03B | $20.31B |
Volume | 1,131,157 | 1,015,599 |
Sector | Health | Energy |
52-Week High | $425.64 | $57.61 |
52-Week Low | $179.42 | $24.71 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $56.18B | $28.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
YPF trades at $51.79, down 0.35% on the day, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with Q2 2026 earnings beating estimates and strong revenue growth from $18.3B in 2025 to $20.6B projected for 2026. Recent developments include a $24B LNG project gaining U.S. financing support and record quarterly cash flow generation.
The outlook remains positive with analyst consensus at Buy (46.7%) and a $56.67 price target representing 9.4% upside. Key risks include political uncertainty in Argentina and execution challenges for major capital projects. The stock offers value with attractive EV/EBITDA of 3.91x but faces margin pressure from high tax burdens.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About YPF Sociedad Anonima American Depositary Shares
YPF is an integrated energy company in Argentina. Its operations span oil and gas exploration and production, transportation, refining, and the marketing of petroleum products.
Read more on YPF →
